MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
äŒæ¥ã³ãŒãMDXG
äŒç€ŸåMiMedx Group Inc
äžå Žæ¥Aug 20, 2007
æé«çµå¶è²¬ä»»è
ãCEOãMr. Joseph H. (Joe) Capper
åŸæ¥å¡æ°837
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 20
æ¬ç€Ÿæåšå°1775 W Oak Commons Court, Ne
éœåžMARIETTA
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·30062
é»è©±çªå·17706519100
ãŠã§ããµã€ãhttps://mimedx.com/
äŒæ¥ã³ãŒãMDXG
äžå Žæ¥Aug 20, 2007
æé«çµå¶è²¬ä»»è
ãCEOãMr. Joseph H. (Joe) Capper
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã